PTG Activators
PTG activators are chemical compounds that directly or indirectly enhance the functional activity of PTG, predominantly via the modulation of cAMP levels within the cell. cAMP is a second messenger that plays a pivotal role in various cellular processes, and its concentration is tightly regulated by the balance between its synthesis by adenylyl cyclase and its degradation by phosphodiesterases. Many PTG activators identified, such as Forskolin and PGE2, function by directly stimulating adenylyl cyclase to increase cAMP production. In contrast, others like IBMX and Rolipram inhibit phosphodiesterases, thereby impeding cAMP degradation and maintaining its high intracellular levels.
The elevated cAMP levels, as a result of the action of these chemical compounds, foster a favourable biochemical environment that promotes PTG activity. For instance, the increase in cAMP levels leads to the activation of protein kinase A, which can then phosphorylate and activate PTG, among other proteins. Thus, by differentially regulating cAMP levels within the cell, these compounds indirectly influence PTG activity. Importantly, the precise effect of these compounds can be context-dependent and influenced by the interplay with other signaling molecules and pathways within the cell.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin is a diterpene that directly activates adenylyl cyclase, leading to an increase in cyclic adenosine monophosphate (cAMP) levels. Elevated cAMP enhances the activity of PTG by fostering a positive biochemical environment that promotes its activity. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX (3-isobutyl-1-methylxanthine) is a nonspecific inhibitor of phosphodiesterases, which degrade cAMP. By inhibiting cAMP degradation, IBMX maintains high cAMP levels, indirectly enhancing PTG activity by creating a favourable biochemical milieu. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $57.00 $159.00 $275.00 $678.00 | 37 | |
Prostaglandin E2 (PGE2) is a lipid compound that can stimulate the production of cAMP via the EP2 or EP4 receptors. This increase in cAMP can enhance PTG activity by promoting a favourable intracellular environment. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram is a selective phosphodiesterase-4 inhibitor. By inhibiting the breakdown of cAMP, Rolipram elevates intracellular cAMP levels and indirectly enhances PTG activity. | ||||||
SQ 22536 | 17318-31-9 | sc-201572 sc-201572A | 5 mg 25 mg | $95.00 $363.00 | 13 | |
SQ 22536 is an adenylyl cyclase inhibitor. By inhibiting the production of cAMP, SQ22536 indirectly reduces PTG activity, making its inclusion here counterintuitive. However, understanding its mechanism provides insights into the regulation of PTG. | ||||||
Zardaverine | 101975-10-4 | sc-201208 sc-201208A | 5 mg 25 mg | $88.00 $379.00 | 1 | |
Zardaverine is a dual inhibitor of phosphodiesterases 3 and 4, thus preventing the degradation of cAMP. This leads to an increase in intracellular cAMP levels and enhances PTG activity. | ||||||
Vinpocetine | 42971-09-5 | sc-201204 sc-201204A sc-201204B | 20 mg 100 mg 15 g | $55.00 $214.00 $2400.00 | 4 | |
Vinpocetine is a selective inhibitor of phosphodiesterase-1. By elevating cAMP levels, it indirectly enhances PTG activity. | ||||||
Etazolate Hydrochloride | 35838-58-5 | sc-201186 sc-201186A | 5 mg 25 mg | $61.00 $255.00 | 5 | |
Etazolate is a phosphodiesterase-4 inhibitor. By preventing the degradation of cAMP, it increases intracellular cAMP levels and indirectly enhances PTG activity. | ||||||
Cilomilast | 153259-65-5 | sc-483188 | 5 mg | $132.00 | 1 | |
Cilomilast is a selective phosphodiesterase-4 inhibitor. It elevates cAMP levels by preventing its degradation, leading to indirect enhancement of PTG activity. | ||||||
Siguazodan | 115344-47-3 | sc-201201 sc-201201A | 5 mg 25 mg | $100.00 $398.00 | ||
Siguazodan is a phosphodiesterase-3 inhibitor. It increases cAMP levels by preventing its degradation, resulting in indirect enhancement of PTG activity. | ||||||